A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab

A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab

Immunotherapy is an effective new approach in the treatment of many malignancies. However, pancreatic ductal adenocarcinoma (PDAC) does not usually respond to immunotherapy. We discuss the case of a patient with metastatic microsatellite instability-high PDAC who had a prolonged response to single-a...

Full description

Bibliographic Details
Main Authors: Annie A. Guedikian, Megan E. Randall, Anita Sharko, William T. Leslie
Format: Article
Language:English
Published: Karger Publishers 2021-09-01
Series:Case Reports in Oncology
Subjects:
metastatic pancreatic ductal adenocarcinoma
mismatch repair deficiency
microsatellite instability
programmed cell death protein 1 inhibitor
Online Access:https://www.karger.com/Article/FullText/519181

Internet

https://www.karger.com/Article/FullText/519181

Similar Items